Mechanism of Action
Melanocortin Receptor Antagonism
AgRP acts as a high-affinity inverse agonist at MC3R and MC4R, receptors tonically activated by alpha-msh/" class="wiki-internal-link">alpha-MSH to suppress appetite and increase energy expenditure. By blocking MC4R in the paraventricular nucleus (PVN) of the hypothalamus, AgRP removes tonic inhibition on feeding circuits. Unlike simple competitive antagonists, AgRP can suppress constitutive MC4R activity, producing effects beyond blocking alpha-MSH alone.
Arcuate Nucleus and Hunger Circuitry
AgRP neurons co-express neuropeptide Y (NPY) and GABA. When activated by ghrelin/" class="wiki-internal-link">ghrelin, low leptin/" class="wiki-internal-link">leptin, or low glucose, these neurons release AgRP (blocking MC4R), NPY (activating NPY1R/NPY5R to stimulate feeding), and GABA (inhibiting POMC neurons). This triple action makes AgRP neurons master switches for hunger. Optogenetic or DREADD activation of AgRP neurons triggers immediate, voracious feeding regardless of energy status.
Peripheral and Metabolic Effects
Beyond hypothalamic circuits, AgRP influences peripheral metabolism by modulating adrenal glucocorticoid secretion and liver glucose output. AgRP expression increases dramatically during fasting, with plasma AgRP levels rising. MC4R blockade in peripheral tissues affects lipid metabolism, insulin secretion from beta cells (MC4R expressed), and thermogenesis. AgRP neurons also project to brain reward areas, linking hunger to motivational salience of food.
Research Summary
Appetite and Obesity
PreclinicalICV injection of AgRP(83-132) in rodents causes hyperphagia lasting 7-10 days following a single dose, demonstrating the remarkable potency and duration of AgRP signaling. Chronic overexpression of AgRP causes obesity, while AgRP knockout mice are lean. Antagonists of AgRP (MC4R agonists) are being developed for obesity; conversely, AgRP mimetics are explored for cachexia and anorexia nervosa where appetite stimulation is needed.
Cachexia and Anorexia
TranslationalIn cancer cachexia and chemotherapy-induced anorexia, AgRP/MC4R pathway suppression drives appetite loss. MC4R knockout mice resist cancer cachexia. Restoring AgRP signaling or blocking MC4R may counter cachexia. Early clinical interest exists in AgRP mimetics for patients with severe weight loss in cancer, AIDS, or anorexia nervosa.
Circadian and Metabolic Timing
EmergingAgRP neuron activity follows circadian patterns, peaking before the active phase in rodents. Disruption of AgRP rhythmicity contributes to metabolic syndrome in shift work models. AgRP also interacts with circadian clock genes, linking energy sensing to time-of-day metabolism. This research suggests timing of eating behavior is regulated partly through AgRP circuit dynamics.
Calculate your AgRP dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Feeding stimulation (animal) | 0.1-1 nmol ICV | Single injection | ICV (intracerebroventricular) |
| Chronic hyperphagia model | 1 nmol/day ICV | Daily x 7 days | ICV |
| SC bioavailability study | 100-500 mcg/kg SC | Single dose | SC |
AgRP is a research tool peptide. ICV administration is required for central hypothalamic effects. No human dosing established.
Interactions
Safety Profile
AgRP is an endogenous peptide with no established safety data for exogenous administration in humans. Animal data shows the primary risk is extreme hyperphagia and weight gain with chronic or high-dose central administration. Systemic SC administration has much lower CNS penetration, limiting efficacy but also central side effects. Given the role in feeding regulation, clinical use would require careful monitoring for weight gain, metabolic changes, and potential effects on reward circuitry.
References
- [1]Ollmann MM, et al. Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science. 1997.
- [2]Gropp E, et al. Agouti-related peptide-expressing neurons are mandatory for feeding. Nature Neurosci. 2005.
- [3]Chen AS, et al. Role of the melanocortin-4 receptor in metabolic rate and food intake. Transgenic Res. 2000.